Is buying CSL shares right now a smart move?

Experts are tipping a strong recovery for the healthcare stock.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The CSL share price could be about to embark on a green streak if bullish experts are to be believed
  • The stock is still trading around 20% below its pre-pandemic highs
  • But one expert thinks that, if all goes well for the stock, it could rocket beyond its previous record high

The CSL Limited (ASX: CSL) share price still hasn't recovered to its pre-pandemic level, which saw it trading solidly above the $300 mark.

Indeed, the S&P/ASX 200 Index (ASX: XJO) healthcare stock is nearly 20% lower than the record high of $342.75 it posted in February 2020.

Could things be about to turn around for the CSL share price? Some experts are tipping it to do big things from here.

Right now, the CSL share price is $275.98.

A scientist examining test results.

Image source: Getty Images

Is now a good time to buy CSL shares?

It's been a rough couple of years for the CSL share price despite plenty of exciting happenings at the company.

Most obviously, it completed its $16 billion acquisition of Swiss giant Vifor Pharma earlier this year.

The ASX-listed healthcare favourite also recently revealed that, Vifor Pharma's contribution included, it expects to post between US$2.7 billion and US$2.8 billion of net profit before tax and amortisation for financial year 2023.

The team at Morgans was pleased by the news, retaining its buy rating and adjusting its price target for CSL shares to $312.20, my Fool colleague James reports. That represents a potential 13% upside.

The broker said strong plasma collections and demand, as well as the addition of Vifor Pharma, "portends strong growth momentum".

Meanwhile, Goldman Sachs remained neutral on the stock following its most recent announcement, tipping it to lift to $291 – a potential 5% gain.

Tribeca Investment Partners portfolio manager Jun Bei Liu is also hopeful about the stock. She said it was one of numerous in the space trading at a reasonable valuation, saying, courtesy of Livewire:

We do think healthcare will perform very well in an uncertain environment. These companies will deliver very strong earnings growth regardless of the economic outlook.

But the most bullish expert is Fairmont Equities founder Michael Gable. My Fool colleague Tony quoted the expert as telling media:

In some ways, CSL might have dropped off people's radar because since the COVID lows [the share price] hasn't really done anything.

It bottomed in February… and now it's starting to outperform the broader index.

You could see CSL with a four in front of it potentially by the end of next year, if it breaks out.

To reach the $400 mark, the CSL share price would have to gain around 45%. No doubt plenty of investors will have their fingers crossed for such a rise.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and Goldman Sachs. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists looking at a tablet.
ASX Share Market News

Where will CSL shares be in 12 months? Brokers weigh in

Analysts remain divided over CSL’s recovery prospects.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why this ASX healthcare share is a retiree's dream for FY27

This defensive business is giving investors rising dividends.

Read more »

Two scientists analysing results on a computer screen.
Broker Notes

Up 88%! Why CSL shares remain an 'appealing' buy today

A top analyst forecasts more outperformance from CSL’s surging shares.

Read more »

Two scientists analysing results on a computer screen.
Earnings Results

Monash IVF Group earnings: FY26 profit slips, outlook improves

The company posted weaker FY26 profit but ends year with improving momentum, dividend, and outlook for growth.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Healthcare Shares

Bell Potter says this ASX healthcare share could rise 200%+

The broker has good things to say about this growing stock.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

4DMedical share price rises as FY26 revenue climbs, losses moderate

4DMedical lifted revenue 21% and improved its adjusted net loss for FY26, while investing in new AI-driven medical imaging solutions.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab

Imricor Medical Systems has teamed up with Philips to launch a new MR-guided cardiac interventions lab, targeting broader clinical adoption.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Why now is the time to buy low on these ASX healthcare shares with up to 84% upside

These two stocks have big upside.

Read more »